©2022 Stanford Medicine
Effect of Tranexamic Acid on Postoperative Bleeding Following Sinus and Nasal Surgery
Not Recruiting
Trial ID: NCT04754230
Purpose
The purpose of the research is to assess the effectiveness of a dose of intravenous
tranexamic acid (TXA) given intraoperatively to reduce postoperative bleeding after
endoscopic sinus or nasal surgery (e.g. septoplasty, endoscopic sinus surgery, turbinate
surgery). This medication has been shown to decrease blood loss during this type of surgery,
but the implications for bleeding following surgery are unclear. Any impact on postoperative
bleeding will be assessed over the first 7 days following surgery leading up to the first
scheduled postoperative clinic visit. Patients will keep a standardized daily diary of their
bleeding experience by indicating on a 0-10 visual analog scale (VAS) their impression of
their bleeding.
The primary outcome is the patient-reported visual analog scale (VAS) bleeding score on each
day after surgery. The secondary outcomes include the the frequency with which the
otolaryngology resident service is requested to evaluate patients in the recovery unit for
postoperative bleeding concerns and the frequency of interventions such as application of
hemostatic materials, packing, cautery, and/or return to the operating room.
Official Title
Effect of Tranexamic Acid on Postoperative Bleeding Following Sinus and Nasal Surgery
Stanford Investigator(s)
Zara Patel, MD
Professor of Otolaryngology - Head & Neck Surgery (OHNS)
Eligibility
Inclusion Criteria:
- Scheduled to undergo elective sinus or nasal surgery (e.g. septoplasty, inferior
turbinate reduction, endoscopic sinus surgery)
- Age 18 or greater
- English-speaking
- Able to provide consent
Exclusion Criteria:
- Minors (age<18)
- Pregnant or may become pregnant by time of surgery
- Prisoners
- Non-English speaking
- Foreign citizens
- Unable to provide consent
- Known pro-thrombotic coagulation disorders
- Active intranasal drug use (e.g. cocaine)
- Surgery is for a sinonasal tumor or other sinus pathology not described in inclusion
criteria
- Enrollment is in conflict with existing study participation
Intervention(s):
drug: Tranexamic Acid 1,000 Mg/10 mL (100 Mg/mL) INTRAVEN VIAL (ML)
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305